<DOC>
	<DOCNO>NCT02743117</DOCNO>
	<brief_summary>This prospective annual release study design evaluate safety 1 new influenza virus vaccine strain include FluMist Quadrivalent 2016-2017 influenza season</brief_summary>
	<brief_title>Study Evaluate Safety 1 New 6:2 Influenza Virus Reassortants Adults 2016-2017 Season</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo-controlled release study enroll approximately 300 healthy adult 18 49 year age . Eligible subject randomly assign 4:1 fashion receive single dose monovalent vaccine placebo intranasal spray . Randomization stratify site . This study conduct 3 site United States America . Each subject receive 1 dose investigational product Day 1 . The duration study participation subject time study vaccination 180 day study vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 18 49 year Written inform consent Subject available telephone Ability understand comply requirement protocol , judge Investigator Concurrent enrollment another clinical study 180 day receipt investigational product ( Day 181 ) History hypersensitivity component vaccine , include egg egg protein serious , life threatening , severe reaction previous influenza vaccination Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( example [ eg ] , asthma ) , chronic metabolic disease ( eg , diabetes mellitus ) , renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year Acute febrile ( great [ &gt; ] 100.0 degree Fahrenheit [ F ] oral equivalent ) and/or clinically significant respiratory illness ( example , cough sore throat ) within 14 day prior randomization Any known immunosuppressive condition immune deficiency disease , include human immunodeficiency virus infection , ongoing immunosuppressive therapy History GuillainBarr√© syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Trivalent</keyword>
	<keyword>Influenza</keyword>
	<keyword>FluMist Quadrivalent</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Prevention</keyword>
	<keyword>Healthy</keyword>
	<keyword>Monovalent</keyword>
</DOC>